Part of the series: 30 Visioneers Shaping the Future of Biotech in 2025
In an age where prevention is finally catching up to cure, MultiplAI Health is at the frontier of a healthcare revolution. By harnessing the power of RNA sequencing and artificial intelligence, the company is building tools to detect complex diseases—like cardiovascular conditions and cancers—before symptoms ever appear. What started as a personal wake-up call for co-founder Mark, a heart attack at 35 that could have been prevented, has evolved into a bold mission: to make early, accurate, and affordable disease detection accessible to all.
Founded alongside renowned cardiologist Dr. Santiago Miriuka and molecular biologist Charlie Luzzani, MultiplAI is developing a new category of diagnostics—one that goes beyond inherited traits to read the real-time signals of disease from the blood itself. In this Q&A, Mark shares the story behind MultiplAI, why RNA is the key to unlocking proactive health at scale, and what it takes to build trust in the next generation of AI-driven medical tools.
1. MultiplAI Health is pioneering early disease detection using RNA sequencing and AI. What led you to focus on this intersection, and how do you see it transforming preventive healthcare?
MultiplAI Health is developing the world's best biomarker product for cardiovascular and other complex diseases. MultiplAI’s proprietary technology uses genomic sequencing to digitize a whole blood sample, and advanced artificial intelligence to transform it into a detailed, actionable health assessment. Our vision is to keep all people healthy using precise analysis that will enable proactive health management to enhance longevity at scale.
MultiplAI is founded by a Cardiologist, Santiago Miriuka, and his patient (me) who had a heart attack at the age of 35, that should have been prevented. With access to biological health data at the molecular level becoming scaleable, we now have more accurate and accessible tools to make preventative healthcare a reality. The third founder, Charlie Luzzani, is a molecular biologist with over a decade together with Santiago developing our expertise in RNA, an ideal source for both hereditary and environmental/acquired health data. These are the building blocks of true preventative healthcare.
2. How does your approach to blood-based diagnostics compare to traditional methods, and what impact could it have on population health outcomes globally?
Our proprietary RNA datasets demonstrate that RNA captures disease genetic signatures and environmental impacts, not just inherited DNA traits. We are building a universally accessible screening test to enable true preventative healthcare at scale.
Key competitive differentiators include:
- Repeatability: RNA is modified by environmental factors contributing to disease and encourages multiple tests to monitor patient outcomes.
- Sensitivity: we detect disease before it shows physical and other clinical symptoms
- Accurate: already superior to today’s standards of care with much potential for improvement
- Affordable: strong unit economic tailwinds in key costs (e.g. sequencing, compute/AI)
- Scaleable: as simple as standard blood work and soon self-administrable, it is a remote / in-home and does not require access to scarce resources (e.g. CT scanners).
Cardiovascular Disease (CVD) is the #1 cause of human mortality (claiming 18 million lives p.a.), and expected to cost humanity over a trillion dollars annually by 2035. We want to change this with universally accessible early screening. Importantly, our approach has the potential to identify many diseases that come in touch with the blood, including many cancers and other complex diseases. Imagine a world without medications for sick people, but instead, products to keep people healthy for longer. That is what we are after.
3. What advice would you give to healthtech founders building AI-driven tools that need both clinical validation and user trust to scale?
In developing clinical products, don't skip steps and be sure to prepare for future steps you should know are coming. This has to do with knowing the dynamics of your space and having clarity regarding the target you are after. For example, in our case it is critical to continue to publish relevant papers about our and related technologies - it is both a source of validation and eventually user trust through the community that needs to accept our products, doctors. Also, involving the right partners to fill gaps in capabilities, or to accelerate results like time to market or turnaround times, is a second pillar of activity. And finally, spend time and energy on developing a robust culture that promotes fast learning and curiosity to resolve challenges, both planned and unexpected. Trust in the potential of these products starts from within.
Links:
Website: https://www.multiplaihealth.com/
LinkedIn: https://www.linkedin.com/company/multiplai-health/
.png)